--- title: "Nexalin Tech | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 14.95 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/285763272.md" datetime: "2026-05-08T18:36:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285763272.md) - [en](https://longbridge.com/en/news/285763272.md) - [zh-HK](https://longbridge.com/zh-HK/news/285763272.md) --- # Nexalin Tech | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 14.95 K Revenue: As of FY2026 Q1, the actual value is USD 14.95 K, missing the estimate of USD 15 K. EPS: As of FY2026 Q1, the actual value is USD -0.11, missing the estimate of USD -0.1. EBIT: As of FY2026 Q1, the actual value is USD -2.12 M. ### Segment Revenue Nexalin Technology, Inc. operates as a single reportable segment. Total revenues, net, for the three months ended March 31, 2026, decreased to $14,950 from $41,015 in the same period of 2025, representing a -64% year-over-year change . - **US Revenue**: $14,950 for the three months ended March 31, 2026, down from $20,443 for the same period in 2025 . - **International Revenue**: $0 for the three months ended March 31, 2026, down from $20,572 for the same period in 2025 .The decrease in revenue was primarily attributed to lower equipment sales to an international customer . ### Operational Metrics - **Cost of Revenues**: Decreased to $1,817 for the three months ended March 31, 2026, from $13,558 in the prior year, an -87% change . - **Gross Profit**: Decreased to $13,133 for the three months ended March 31, 2026, from $27,457 in the prior year, a -52% change . - **Gross Margin**: Increased to 88% for the three months ended March 31, 2026, compared to 66% in the prior year, primarily due to a change in revenue mix with higher-margin licensing fees . - **Total Operating Expenses**: Increased by 5% to $2,133,035 for the three months ended March 31, 2026, from $2,038,682 in the prior year . - **Professional Fees**: Increased by 35% to $495,296 from $367,816 . - **Salaries and Benefits**: Increased by 49% to $498,560 from $335,358 . - **Selling, General and Administrative (SG&A)**: Decreased by -15% to $792,797 from $929,220 . - **Research and Development (R&D)**: Decreased by -15% to $346,382 from $406,288 . - **Loss from Operations**: Increased by 5% to -$2,119,902 for the three months ended March 31, 2026, from -$2,011,225 in the prior year . - **Net Loss**: Increased by 5% to -$2,096,837 for the three months ended March 31, 2026, from -$1,988,337 in the prior year . ### Cash Flow - **Net Cash Used in Operating Activities**: -$1,712,988 for the three months ended March 31, 2026, compared to -$1,426,214 for the same period in 2025 . - **Net Cash Provided by Investing Activities**: $1,509,679 for the three months ended March 31, 2026, compared to $1,473,758 for the same period in 2025 . - **Net Cash Provided by Financing Activities**: $756,421 for the three months ended March 31, 2026, due to sales under the At-the-Market (ATM) program, with no such financing in the prior year . ### Unique Metrics - **Research and Development Expenses by Project (Q1 2026 vs Q1 2025)**: - Clinical trials: $198,445 vs $61,352 . - EDC Build: $55,800 vs $18,050 . - HALO project: $88,767 vs $298,037 . - SYNC project: $0 vs $23,713 . - Other research and development: $3,370 vs $5,136 . - **ATM Program**: For the three months ended March 31, 2026, Nexalin Technology, Inc. sold 1,395,300 shares of common stock for net proceeds of approximately $756,000 . As of March 31, 2026, a total of 2,086,707 shares have been sold for gross proceeds of approximately $1,423,000 under the program . ### Future Outlook and Strategy Nexalin Technology, Inc. expects to continue incurring operating losses and negative cash flow in 2026 and beyond as it executes development plans and potential strategic initiatives . The company’s priorities include obtaining FDA clearance for its Gen-2 and Gen-3 devices and executing U.S. clinical trials . Management believes additional capital may be required to fund planned clinical and operating activities, including a pivotal insomnia study, beyond current cash resources . ### Related Stocks - [NXL.US](https://longbridge.com/en/quote/NXL.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Abaxx to Launch Silver Singapore Futures on May 22, 2026 | ABXXF Stock News](https://longbridge.com/en/news/286762247.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)